@article {FERRONI4705, author = {PATRIZIA FERRONI and MARIO ROSELLI and ORESTE C. BUONOMO and ANTONELLA SPILA and ILARIA PORTARENA and ANASTASIA LAUDISI and MARIA G. VALENTE and SILVANA P. PIRILLO and LUCIO FORTUNATO and LEOPOLDO COSTARELLI and FRANCESCO CAVALIERE and FIORELLA GUADAGNI}, title = {Prognostic Significance of Neutrophil{\textendash}to{\textendash}lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer}, volume = {38}, number = {8}, pages = {4705--4712}, year = {2018}, doi = {10.21873/anticanres.12777}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: To investigate whether neutrophil{\textendash}to{\textendash}lymphocyte ratio (NLR) might represent an additional biological criterion able to identify patients with worse prognosis within the 8th edition TNM prognostic staging system for breast cancer (BC). Patients and Methods. Pre-treatment NLR was retrospectively analyzed in 475 BC women prospectively followed for a mean time of 3.8 years. The optimal NLR cutoff, identified by ROC analysis, was set at 2. Results: Elevated pre-treatment NLR was associated with worse disease-free survival (DFS) (HR=2.28) and overall survival (OS) (HR=3.39). The prognostic value of NLR was mostly evident in stage I BC (HR for DFS=2.89; HR for OS=1.30), in whom NLR significantly stratified patients who developed distant metastasis (HR= 4.62), but not local recurrence. Conclusion: NLR might provide important information in risk stratification, especially in stage I BC patients in whom the presence of a high NLR might raise the question as to whether they should be more aggressively managed.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/38/8/4705}, eprint = {https://ar.iiarjournals.org/content/38/8/4705.full.pdf}, journal = {Anticancer Research} }